Shots:
- Imfinzi has been approved in the EU and the UK for an additional dosing option (1500mg, fd, q4w) in LA, unresectable NSCLC in adults whose tumors express PD-L1 on at least 1% of tumor cells and whose disease has not progressed following platinum-based CRT
- New option extends dosing from 2 to 4wks. thus, reducing medical visits and improving patient convenience. The approval is based on multiple clinical trials that include P-III PACIFIC study in NSCLS patients and P-III CASPIAN study in ES-SCLC patients
- Durvalumab is a human mAb targeting PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80
Click here to read full press release/ article | Ref: AstraZeneca | Image: Business Standard
The post AstraZeneca’s Imfinzi (durvalumab) New Dosing Option Receives Approval for NSCLC in the EU & UK first appeared on PharmaShots.
